BioSpace News Archive

CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation

CPhI South East Asia’s first visit to Bangkok has stimulated a market resurgence, with pre-registration numbers tripling and exhibition growth of 50%

New member brings 25 years of experience in health care delivery and management, public policy, and public health

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

Leti, a research institute of CEA Tech, in collaboration with CEA’s Fundamental Research Divisionand INSERM, has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 – a viral protein that is key to an HIV vaccine – and optimize the CpG adjuvant’s effect.

WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments of about $220 million, and will be entitled to royalties based on global sales of these programs.

London-based medical device regulatory consultancy Quality First International now offers post-Brexit UK representation services that will become mandatory for medical device manufacturers located outside the UK

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announce the names of the ten Patient Entrepreneurs chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Awards in Oncology.

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to launch a phase 2 clinical trial in Friedreich’s Ataxia with its lead candidate, MIN-102.

The positive topline results from this trial were previously announced, but the full results of safety, efficacy, and other clinical data are now available online.